
PENUMBRA INC
PENNYSETrading Snapshot
- Day Range
- $324.22 โ $329.17
- 52-Week Range
- $221.26 โ $362.41
- Volume
- $2.13B
- Avg Volume
- $2.10B
- Shares Outstanding
- 39.4M
- Next Earnings
- Sep 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.40B
- Last Q Revenue
- $390M
- P/E Ratio
- 79.7
- P/S Ratio
- 8.5x
- EPS (TTM)
- $4.08
- Dividend Yield
- 0.00%
Why Investors Own PEN
- โHigh-growth profile โ revenue up +2.4% YoY with expanding US Equity exposure.
- โHealthy economics โ 64% gross margin and 7% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About PENUMBRA INC
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates

TFX vs. PEN: Which Stock Is the Better Value Option?
TFX vs. PEN: Which Stock Is the Better Value Option?

Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?
AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.

Penumbra, Inc. Reports Second Quarter 2026 Financial Results
Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.
Penumbra Q2 EPS $0.88 Misses $1.20 Estimate, Sales $390.046M Beat $389.009M Estimate
Penumbra (NYSE:PEN) reported quarterly earnings of $0.88 per share which missed the analyst consensus estimate of $1.20 by 26.67 percent. This is a 23.48 percent decrease over earnings of $1.15 per share from the same

Penumbra (PEN) Following THUNDERBOLT Debut, Is The Stock A Bargain Or Fairly Valued
Penumbra (PEN) is back in focus after Novant Health reported successful use of its newly cleared THUNDERBOLT computer assisted vacuum thrombectomy system at a North Carolina comprehensive stroke center. See our latest analysis for Penumbra. At a share price of $318.73, Penumbra has seen a 1 year total shareholder return of 36.74%, while the 3 year and 5 year total shareholder returns of 3.46% and 19.72% suggest more moderate longer term progress as investors weigh new products like...

Penumbra (PEN) Wins FDA Clearance For THUNDERBOLT After Strong Stroke Study
Penumbra (NYSE:PEN) received FDA clearance for its THUNDERBOLT computer-assisted vacuum thrombectomy system for acute ischemic stroke treatment. The THUNDER study reported strong safety and efficacy results for THUNDERBOLT in stroke care. A leading stroke center has begun using THUNDERBOLT in clinical practice, expanding its real world footprint. Penumbra, traded on the NYSE under ticker PEN, focuses on medical devices for neuro and vascular conditions, including stroke. The FDA clearance...